Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Free Cash Flow (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Free Cash Flow for 17 consecutive years, with -$5.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 125.53% to -$5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.1 million through Dec 2025, down 224.39% year-over-year, with the annual reading at -$31.1 million for FY2025, 224.39% down from the prior year.
  • Free Cash Flow hit -$5.4 million in Q4 2025 for Integra Lifesciences Holdings, down from $25.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $84.7 million in Q2 2021 to a low of -$40.2 million in Q1 2025.
  • Historically, Free Cash Flow has averaged $27.7 million across 5 years, with a median of $23.4 million in 2024.
  • Biggest five-year swings in Free Cash Flow: surged 1352.99% in 2021 and later crashed 13906.53% in 2025.
  • Year by year, Free Cash Flow stood at $41.8 million in 2021, then skyrocketed by 69.36% to $70.9 million in 2022, then crashed by 51.73% to $34.2 million in 2023, then plummeted by 38.21% to $21.1 million in 2024, then tumbled by 125.53% to -$5.4 million in 2025.
  • Business Quant data shows Free Cash Flow for IART at -$5.4 million in Q4 2025, $25.8 million in Q3 2025, and -$11.2 million in Q2 2025.